Longevity & Cellular

For cellular-energy and longevity research in 2026, the three most-compared in-vitro tools are the NAD+ research pen, the MOTS-c peptide pen and the SS-31 peptide pen. Each targets a distinct biological mechanism: NAD+ is a redox coenzyme studied in sirtuin and PARP signalling pathways, whereas MOTS-c and SS-31 are mitochondrially associated peptides examined for roles in AMPK activation and cardiolipin binding respectively [1]. All materials discussed on this page are supplied for laboratory and in-vitro research use only.

Current price and availability for all three must be confirmed directly with Veyvora prior to any procurement decision; these figures are not reproduced here to avoid presenting stale commercial data.

Veyvora’s longevity research catalogue for 2026 contains three distinct pen-format tools — the NAD+ research pen, the MOTS-c peptide pen and the SS-31 peptide pen. Each occupies a separate mechanistic category and is supplied exclusively for in-vitro laboratory research use.

NAD+ Research Pen

NAD+ (nicotinamide adenine dinucleotide) is a pyridine dinucleotide coenzyme studied in redox biology, sirtuin activation and PARP-mediated DNA-repair signalling. Research interest centres on coenzyme pool size and the enzymes that regulate it, NAMPT, NMNAT and CD38, rather than on peptide–membrane interactions. The NAD+ 1000 research pen is listed in the Veyvora 2026 catalogue as a 3 mL pen-format device delivering 300 clicks at 133 µg per click, supplied with a dosing card and 31G 6 mm pen needles. Operators must confirm current availability and price directly with Veyvora before any procurement decision, as these values are not reproduced here.

MOTS-c and SS-31 Peptide Pens

MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA, studied for its activity on AMPK and folate–AICAR signalling pathways [1]. SS-31 (elamipretide) is a synthetic tetrapeptide examined for its capacity to associate with cardiolipin on the inner mitochondrial membrane [1]. Neither peptide shares a mechanistic category with NAD+ coenzyme biology, and current peer-reviewed literature does not treat the three entities as interchangeable research tools. For the combined research context of these two mitochondrial peptides, MOTS-c + SS-31 research explained provides the relevant background.

Veyvora states that each batch across all three pen formats is tested by two independent laboratories using HPLC, mass spectrometry and endotoxin assay, with a reported purity threshold above 98% (Veyvora quality documentation, 2026). Researchers interpreting batch certificates of analysis should consult how to read HPLC purity before drawing conclusions from the purity field.

The three research tools covered in this guide operate at different levels of the evidence hierarchy. NAD+ coenzyme biology is supported by extensive mechanistic and preclinical literature addressing NAMPT, NMNAT and CD38 pathways, sirtuin activation and PARP signalling. MOTS-c and SS-31 research sits predominantly at the peptide-mechanism and early preclinical stage, with MOTS-c characterised through AMPK and folate–AICAR pathway studies and SS-31 through cardiolipin-binding assays on the inner mitochondrial membrane [1].

What the Evidence Does and Does Not Support

Mechanistic findings from cell-free or cell-based assays establish pathway interactions under controlled in-vitro conditions; they do not establish efficacy or safety in living systems. Preclinical rodent data, where it exists for any of these entities, cannot be extrapolated to human outcomes without independent clinical validation. No single peer-reviewed paper published between 2024 and 2026 treats NAD+, MOTS-c and SS-31 as interchangeable longevity tools or presents a head-to-head in-vitro methods comparison across all three [1]. Researchers should treat each entity as mechanistically distinct and select assay designs accordingly.

All materials available through the Veyvora research peptide catalogue are supplied for in-vitro laboratory research only.

Researchers who have reviewed the procurement and verification criteria on this page should confirm batch identity against the certificate of analysis before any in-vitro work begins. The pages below address the distinct tasks that follow from that decision.

Analytical Verification

Before accepting a consignment, confirm that the reported HPLC purity meets the stated threshold and that the molecular weight matches the theoretical value for the entity ordered. How to read HPLC purity explains the analytical method and what each field in a purity report represents. Once the CoA is in hand, verify your batch against its CoA provides a structured checklist for cross-referencing batch number, identity, purity and stability data.

Mechanistic and Comparative Context

For researchers deciding between the two mitochondrial peptide tools, the MOTS-c and SS-31 comparison sets out format and specification differences in consistent terms. The mechanistic basis for studying MOTS-c and SS-31 together is covered in MOTS-c + SS-31 research explained, which addresses the distinct signalling pathways, AMPK/folate–AICAR for MOTS-c and cardiolipin binding for SS-31, without conflating them with NAD+ coenzyme biology. For the coenzyme itself, NAD+ research explained provides the relevant mechanistic background.